Billerica, Massachusetts-based Insulet Corporation, maker of the OmniPod Insulin pump, has just announced that it received the FDA clearance to commercialize its latest product the Omnipod Dash ...

Both moves have shown up in margin expansion. Insulet is currently enjoying adoption of its Omnipod Dash, which allows for access to personal blood glucose and insulin readings from the pump to a ...

Editor's note: The headline and body of this article has been edited to clarify that Samsung's integration with the Omnipod Dash have not yet been implemented. Samsung Galaxy smartphones will be ...

Insulet PODD appears well-poised on solid prospects in the diabetes market. The company continues to gain from strong Omnipod 5 and Omnipod DASH uptake globally. The stock carries a Zacks Rank #1 ...

Insulet PODD has seen impressive momentum in the past year, with its shares soaring 37.4%. It has significantly outperformed the industry’s 0.5% fall and the S&P 500 composite’s 17.5% gain. Presently ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), announced on October 17, 2022, a Medical Device Correction for all Omnipod DASH® Personal Diabetes Managers (PDMs) distributed globally.

Until Insulet's Omnipod came on the market at the end of 2005, all insulin pumps consisted of a controller and insulin reservoir attached to the injection site by a long flexible tube. The Omnipod ...

Insulet’s chief growth officer said: “colour has the power to differentiate a brand,” with mango orange adorning Omnipod’s ...

Insulet Corporation PODD continues to gain on solid prospects in the diabetes market. The company is progressing well with respect to its four-pillar strategy. Yet, macroeconomic woes exert ...